Press coverage about Recro Pharma (NASDAQ:REPH) has trended positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Recro Pharma earned a media sentiment score of 0.50 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- $14.90 Million in Sales Expected for Recro Pharma, Inc. (REPH) This Quarter (americanbankingnews.com)
- -$0.53 Earnings Per Share Expected for Recro Pharma, Inc. (REPH) This Quarter (americanbankingnews.com)
- Recro Pharma Reports Inducement Grants for New Staff (finance.yahoo.com)
- ETFs with exposure to Recro Pharma, Inc. : June 16, 2017 (finance.yahoo.com)
- Recro Pharma Reports Inducement Grants for New Staff – GlobeNewswire (press release) (globenewswire.com)
A number of equities analysts recently weighed in on REPH shares. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $8.75 price target on the stock in a report on Friday, March 10th. Aegis reissued a “buy” rating and issued a $11.00 price target on shares of Recro Pharma in a report on Monday, March 27th. Roth Capital set a $20.00 price target on shares of Recro Pharma and gave the stock a “buy” rating in a report on Saturday, May 13th. Finally, Janney Montgomery Scott downgraded shares of Recro Pharma from a “buy” rating to a “fair value” rating and cut their price target for the stock from $21.00 to $6.50 in a report on Wednesday, June 14th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Recro Pharma has an average rating of “Buy” and an average price target of $14.14.
Shares of Recro Pharma (NASDAQ REPH) traded up 2.84% during midday trading on Thursday, hitting $6.88. The stock had a trading volume of 209,951 shares. The firm’s market cap is $131.06 million. Recro Pharma has a 12 month low of $5.81 and a 12 month high of $12.50. The stock’s 50 day moving average price is $7.53 and its 200 day moving average price is $7.67.
Recro Pharma (NASDAQ:REPH) last announced its earnings results on Thursday, May 11th. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.15. The business had revenue of $18.74 million for the quarter, compared to analysts’ expectations of $15.58 million. Recro Pharma had a negative return on equity of 61.09% and a negative net margin of 45.15%. On average, equities analysts forecast that Recro Pharma will post ($2.35) EPS for the current fiscal year.
In other news, major shareholder Stonepine Capital Management, sold 217,308 shares of Recro Pharma stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $7.70, for a total transaction of $1,673,271.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider James E. Flynn sold 110,447 shares of Recro Pharma stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $6.39, for a total value of $705,756.33. The disclosure for this sale can be found here. Insiders sold 1,187,699 shares of company stock worth $8,749,514 over the last three months. Insiders own 21.60% of the company’s stock.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with our FREE daily email newsletter.